Journal of Oncology

Research Article

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Table 3

Selected patient and tumor characteristics, EGFR, MET, p-53, HPV-16, and p16 status and response to CCRT.
nPrimary siteGenderAgeResponseEGFREGFREGFRMETMETMETp-53HPV-16p16
(years)(IHC)(FISH)(mRNA)(IHC)(FISH)(FISH)(IHC)(DNA)(IHC)
Oral cavityW69PR LLGHNTRGAIN5NN
Oral cavityM66PR DIHPTRGAIN 90NN
Oral cavityM59PR TRHNTRGAIN 90NN
Oral cavityM82CR DIHNLPGAIN 90PN
Oral cavityM61NE TRLPLPGAIN 90PN
Oral cavityM69PD DILNDINORMAL 90——
Oral cavityW41PD DILPTRGAIN80—N
Oral cavityW60CR TRHPTRGAIN0NN
Oral cavityM44CR TRHPTRGAIN30–40PP
Oral cavityM60ED DILPTRGAIN 90NP
Oral cavityW59PD DIHPLPGAIN20–30NN
Oral cavityW55CR ——Undet.— — ————
OropharynxM57CR AMPLHPLPGAIN 90NN
OropharynxW36CR DILNLPGAIN 5PP
OropharynxM59CR DILNLPGAIN0NN
OropharynxW55CR DILPLPGAIN30–40PP
OropharynxM69PR DIUndet.NDINORMAL——P
OropharynxM46CRNE—H— — ——NP
OropharynxM73PD TRHNTRGAIN0NN
OropharynxM67SD TRHPDINORMAL70–80NN
HypopharynxM46ED TRHNHPGAIN 90N—
HypopharynxW64PRNE—L— ——N—
HypopharynxM56ED TRLPDINORMAL 90PN
HypopharynxW56PR DILN — —0——
LarynxM55CR DIHNDINORMAL0NN
LarynxM68PR DILNTRGAIN 90NN
LarynxM60ED ——Undet.— —————
LarynxM42PR DILNDINORMAL 90NN
LarynxM76CR LLGLNDINORMAL30–40NN
LarynxM74EDNEDILN — —0N—
LarynxW46SD DILPTRGAIN5–10NP
LarynxM74ED DILPTRGAIN 90NP
LarynxM67PD LLGHNTRGAIN 90NN
LarynxM54CR DIHNTRGAIN0NN
LarynxM54PR DIUndet.NDINORMAL——N
Paranasal SinusesM65SD LLGHPTRGAIN 90NN
Major Salivary GlandM74PR TRLNLPGAIN 90NN
n = sample order number, M = man, W = woman.
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = nonevaluable, ED = early death.
LLG = low level gain, DI = disomy, HP = high polysomy, LP=low polysomy, TR = trisomy, AMPL = amplification.
P = positive, N = negative, H = high, L = low, Undet. = undetermined by real time PCR.